Treatment of intestinal parasitic disease.
Although improved sanitation in the United States has resulted in a general diminution in the prevalence of intestinal parasitic infections, some, such as enterobiasis, are not reduced by improved environmental or water sanitation and others, such as amebiasis and hookworm infection, persist in foci. Other infections, notably giardiasis, have increased due to the travels of American tourists in other countries where environmental sanitation is poor. North American physicians, therefore, may expect at some time to have to treat parasitic infections. Favored chemotherapeutic agents currently are: for amebiasis--metronidazole and diiodohydroxyquin; for giardiasis--metronidazole; for tapeworm infections--niclosamide; for enterobiasis--pyrantel pamoate, piperazine citrate, or pyrvinium pamoate; for ascariasis--piperazine citrate; for stronglyoidiasis--thiabendazole; for trichuriasis--mebendazole; for hookworm infection--pyrantel pamoate; for schistosomiasis japonica--tartar emetic; and for schistosomiasis mansoni--niridazole.
D000562:Amebiasis / Q000188:drug therapy; D000923:Anticestodal Agents / Q000627:therapeutic use; D000969:Antinematodal Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001196:Ascariasis / Q000188:drug therapy; D001447:Balantidiasis / Q000188:drug therapy; D002590:Cestode Infections / Q000188:drug therapy; D005873:Giardiasis / Q000188:drug therapy; D006725:Hookworm Infections / Q000188:drug therapy; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D010123:Oxyuriasis / Q000188:drug therapy; D012552:Schistosomiasis / Q000188:drug therapy; D014235:Trichinellosis / Q000188:drug therapy; D014257:Trichuriasis / Q000188:drug therapy
D000923:Anticestodal Agents; D000969:Antinematodal Agents; D000981:Antiprotozoal Agents